A landmark Phase 3 trial has delivered the first positive result for Stargardt disease treatment — but the therapeutic landscape is shifting fast. Prof. Maximilian Pfau (SWITZERLAND) enjoys a discussion with Prof. Carel Hoyng (THE NETHERLANDS) and Dr. Karolina Kaminska (SWITZERLAND) on the ABCA4 disease spectrum, the groundbreaking discovery of AP5 complex-related macular dystrophy, and emerging therapies from oral drugs to gene-specific approaches.
Members can continue the conversation in the EURETINA Forum.
Browse all podcast episodes here.
Listen on your preferred podcast player:
